MDS Pharma Services Strengthens Therapeutic Focus on Respiratory and Metabolic Disorders
20 Maggio 2008 - 2:00PM
PR Newswire (US)
Dr. Bernard Tisserand and Dr. Jonny Salyer appointed Executive
Medical Directors to provide leadership and expertise for late
stage clinical studies KING OF PRUSSIA, PA, May 20
/PRNewswire-FirstCall/ -- MDS Pharma Services, a leading provider
of innovative drug discovery and development solutions, has named
two experienced medical professionals to lead its late stage
clinical trial management activities related to respiratory
ailments and metabolic disorders. Dr. Bernard Tisserand and Dr.
Jonny L. Salyer have been named Executive Medical Directors for
Respiratory Disorders and Metabolic Disorders, respectively. These
therapeutic areas represent serious global public health concerns
and are key areas of focus for MDS Pharma Services' customers.
Respiratory disorders include conditions such as asthma, allergic
rhinitis, chronic obstructive pulmonary disease (COPD), and
community acquired pneumonia (CAP), while metabolic disorders
include diabetes, dyslipidemia, obesity and metabolic syndrome,
which is defined as a cluster of conditions that damage the
cardiovascular system. According to the Centers for Disease Control
and Prevention, one-third of the U.S. adult population is currently
obese, and more than 200 million people worldwide have diabetes.
The World Health Organization estimates that 300 million people
suffer from asthma, the most common chronic disease among children,
and that 210 million people have COPD, which is predicted to become
the fourth leading cause of death worldwide by 2030.
"Pharmaceutical companies are pursuing clinical research programs
to address these disorders, and we have made a strategic decision
to become a leader in these key therapeutic arenas by establishing
dedicated teams headed by experienced medical professionals," said
MDS Pharma Services President David Spaight. "In the past 10 years,
MDS Pharma Services has managed over 150 clinical projects
involving respiratory conditions and metabolic disorders. With
expert project teams in Africa, Asia Pacific, Europe, Latin America
and North America, we can offer our clients worldwide access to
patients with these conditions." Dr. Tisserand has held a number of
senior positions in clinical operations and project management at
MDS Pharma Services. In his earlier roles, he managed teams of
project directors, project leaders and clinical research associates
supporting studies in asthma, allergic rhinitis, COPD, CAP and
other major therapeutic areas. He earned his Doctorate in Medicine
from Rene Descartes in Paris and has been with MDS Pharma Services
for eighteen years. Dr. Salyer has nearly 30 years of relevant
experience in research, medicine and the contract research
industry. Prior to joining MDS, she worked for a leading provider
of central laboratory services in Indianapolis, where she served as
Director of Medical Affairs since 2001, supporting Phase I-IV
clinical research. She earned her Bachelor's Degrees in Chemistry
and Microbiology from Indiana University in Bloomington, and her
Doctor of Medicine degree from that institution's School of
Medicine in Indianapolis. In addition to respiratory and metabolic
disorders, other areas of therapeutic focus for MDS Pharma Services
include oncology, vaccines, and diseases of the cardiovascular and
central nervous systems. About MDS Pharma Services MDS Pharma
Services is committed to delivering quality service on time. We
offer a full spectrum of resources to meet the drug discovery and
development needs of the pharmaceutical and biotechnology
industries. With numerous facilities strategically located around
the world, we apply advanced scientific and technological expertise
throughout the drug discovery and development process - from lead
optimization, pre-IND research, early clinical research
(bioequivalence, phases I-IIa) and bioanalysis through to global
clinical development (phases IIb-IV), central lab and centralized
cardiac services. For more information, visit our website at
http://www.mdsps.com/. MDS Pharma Services is a business unit of
MDS Inc. (TSX: MDS; NYSE: MDZ), a global life sciences company that
provides market-leading products and services that our customers
need for the development of drugs and diagnosis and treatment of
disease. We are a leading global provider of pharmaceutical
contract research, medical isotopes for molecular imaging,
radiotherapeutics, and analytical instruments. MDS has more than
5,500 highly skilled people in 29 countries. Find out more at
http://www.mdsinc.com/ or by calling 1-888-MDS-7222, 24 hours a
day. DATASOURCE: MDS Pharma Services CONTACT: For Investors: Kim
Lee, (416) 213-4721, ; For Media: Charlene McGrady, (610) 239-7900
ext. 231,
Copyright